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Natural killer (NK) cells are known to target cancer stem cells and undifferentiated 
tumors. In this paper, we provide a novel strategy for expanding large numbers of 
super-charged NK cells with significant potential to lyse and differentiate cancer stem 
cells and demonstrate the differences in the dynamics of NK cell expansion between 
healthy donors and cancer patients. Decline in cytotoxicity and lower interferon (IFN)-γ 
secretion by osteoclast (OC)-expanded NK cells from cancer patients correlates with 
faster expansion of residual contaminating T  cells within purified NK  cells, whereas 
healthy donors’ OCs continue expanding super-charged NK cells while limiting T cell 
expansion for up to 60 days. Similar to patient NK cells, NK cells from tumor-bearing 
BLT-humanized mice promote faster expansion of residual T cells resulting in decreased 
numbers and function of NK cells, whereas NK cells from mice with no tumor continue 
expanding NK  cells and retain their cytotoxicity. In addition, dendritic cells (DCs) in 
contrast to OCs are found to promote faster expansion of residual T cells within purified 
NK cells resulting in the decline in NK cell numbers from healthy individuals. Addition of 
anti-CD3 mAb inhibits T cell proliferation while enhancing NK cell expansion; however, 
expanding NK cells have lower cytotoxicity but higher secretion of IFN-γ. Expansion 
and functional activation of super-charged NK cells by OCs is dependent on interleukin 
(IL)-12 and IL-15. Thus, in this report, we not only provide a novel strategy to expand 
Abbreviations: CSCs, cancer stem-like cells; DCs, dendritic cells; FBS, fetal bovine serum; HLA, human leukocyte antigen; 
Hr, human recombinant; IFN, interferon; IL, interleukin; KIR, killer cell immunoglobulin-like receptor; KLRG1, killer cell 
lectin-like receptor G1; MHC, major histocompatibility complex; NK, natural killer; OCs, osteoclasts; OSCSCs, oral squamous 
carcinoma stem-like cells.
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sTaTeMenT OF TranslaTiOnal 
releVance
Osteoclast (OC)-induced expansion of highly purified cancer 
patients’ natural killer (NK) cells and those from tumor-bearing-
humanized mice are limited because of the outgrowth of the small 
population of contaminating T cells. These results may provide 
in part an explanation for why NK cells decrease in number in 
cancer patients. Moreover, we show that dendritic cells (DCs) 
expand T cells, whereas OCs expand NK cells suggesting micro-
environmental differences for the expansion of T and NK cells. 
In addition, we designed a strategy to expand large numbers of 
super-charged NK cells for use in immunotherapeutic strategies 
to eliminate cancer stem cells and control tumor growth by dif-
ferentiation of stem-like/poorly differentiated tumors. Our paper 
has a significant translational focus, which should facilitate future 
cancer immunotherapies.
inTrODUcTiOn
Natural killer cells lyse and differentiate cancer stem cells/
undifferentiated tumors with lower expression of major histo-
compatibility complex (MHC) class I, CD54, B7H1, and higher 
expression of CD44 (1, 2). Medium and high cytotoxic activity of 
peripheral-blood lymphocytes are associated with reduced can-
cer risk, and high NK-cell infiltration of the tumor is associated 
with a better prognosis (3, 4), whereas low activity is associated 
with increased cancer risk (5).
Suppression of NK  cells is mediated by downregulation of 
NK receptors in the tumor microenvironment (6–13). Function 
of NK cells was shown previously to be significantly reduced in 
tumor patients (5, 6, 8–12, 14–16).
Several in  vitro NK expansion techniques have been devel-
oped to allow for a higher therapeutic cell dose (Table S1 in 
Supplementary Material) (17–25). The stimulation of peripheral 
blood mononuclear cells (PBMCs) or purified population of 
NK cells with feeder cells such as K562 cells expressing interleukin 
(IL)-15 and 41BB ligand, EBV-TM-LCL, Wilm’s tumor, or irradi-
ated PBMCs have resulted in greater numbers of NK cells with 
adequate function (Table S1 in Supplementary Material) (23, 26, 
27). The generated NK cells expressed higher levels of NKG2D, 
natural cytotoxicity receptors, DNAM-1, and ICAM-1 (25). Thus, 
various methods to obtain ex vivo expanded, activated, and CD3+ 
T  cell-depleted NK  cells have been established for clinical use 
(28). In addition, Miller and colleagues established the safety and 
efficacy of adoptive cellular transfer of human leukocyte antigen-
haploidentical NK  cells in patients with advanced cancer (29). 
Additionally, clinical trials have shown that allogeneic NK cells 
play a therapeutic role in solid tumors and are safe for transfer 
into patients (30–32).
Immunotherapy with NK cells has been limited due to inability 
to obtain sufficient numbers of highly functional NK cells. In this 
paper, we provide a novel strategy to expand highly functional 
NK cells using OCs as feeder cells, at the levels which are sig-
nificantly superior to those established by other methodologies 
(Table S1 in Supplementary Material). In addition, expansion 
of patients’ NK  cells unlike NK  cells from healthy individuals 
is significantly limited due to the expansion of a small fraction 
of contaminating T cells which could potentially crowd out or 
inhibit NK cell expansion by their faster proliferating capability. 
This trend was also seen in NK cell cultures from tumor-bearing-
humanized mice.
MaTerials anD MeThODs
cell lines, reagents, and antibodies
RPMI 1640 complete medium with 10% fetal bovine serum (FBS) 
(Gemini Bio-Product) was used for cell cultures. Oral squamous 
carcinoma cells and oral squamous carcinoma stem-like cells 
(OSCSCs) were isolated from cancer patients with tongue tumors 
at UCLA (2, 33–35). Alpha-MEM (Life Technologies, CA, USA) 
with 10% FBS was used for OCs and DCs cultures. M-CSF was 
purchased from Biolegend (CA, USA) and RANKL, GM-CSF, 
and IL-4 were purchased from PeproTech (NJ, USA) and rh-IL-2 
was obtained from NIH-BRB. Human CD3/CD28 T cell activator 
was purchased from Stem Cell Technologies.
Antibodies for MHC-I, KIR2, KIR3, CD44, CD54, B7H1, 
CD16, NKG2D, MICA/B, KLGR1, CD45, CD3/16/56, CD8, 
CD3, CD4, GL3, NKp40, NKp30, NKp44, NKp46, and CD94 
were purchased from Biolegend (San Diego, CA, USA). ULBP 
1–6 antibodies were purchased from R&D Systems. Propidium 
iodide (PI) was purchased from Sigma (St. Louis, MO, USA). 
sAJ2 was prepared as described previously (35).
Purification of nK cells and T cells from 
human PBMcs and hu-BlT splenocytes
Natural killer cells and T cells were purified as described previ-
ously (36). T cells from hu-BLT splenocytes were positively puri-
fied using isolation kits from Stem Cell Technologies (Stem Cell 
Technologies, Vancouver, BC, Canada).
super-charged NK cells, but also demonstrate that rapid and sustained expansion of 
residual T cells within the purified NK cells during expansion with DCs or OCs could be 
a potential mechanism by which the numbers and function of NK cells decline in cancer 
patients and in BLT-humanized mice.
Keywords: natural killer cells, osteoclasts, hu-BlT mice, osteoclast-expanded natural killer cells, saJ2
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Purification of Monocytes and generation 
of Ocs from hu-BlT Mice and Ocs and 
Dcs from human PBMcs
The study as well as the procedures were approved by the UCLA 
Institutional Review Board (IRB), and all participants signed 
written informed consent in accordance with the Declaration of 
Helsinki. Human monocytes were purified as described previ-
ously (36). Monocytes from hu-BLT mice were positively isolated 
from bone marrow using human CD14 isolation kit (eBioscience, 
San Diego, CA, USA). Greater than 95% purity was achieved for 
each subset based on flow cytometric analysis. Monocytes were 
differentiated to OCs by treating with M-CSF (25  ng/ml) and 
RANKL (25 ng/ml) for 21 days. To obtain DCs, human mono-
cytes were treated with GM-CSF (150 ng/ml) and IL-4 (50 ng/
ml) for 7 days.
expansion of nK cells
Human purified and hu-BLT enriched NK  cells were activated 
with rh-IL-2 (1,000  U/ml) and anti-CD16mAb (3  μg/ml) for 
18–20 h before they were cocultured with feeder cells and sAJ2. 
The culture media was refreshed with rh-IL-2 every 3 days.
Tumor implantation and Tissue 
Preparation from hu-BlT Mice
Animal research described in this manuscript was performed 
under the written approval of the UCLA Animal Research 
Committee (ARC) in accordance to all federal, state, and local 
guidelines. Combined immunodeficient NOD.CB17-Prkdcscid/J 
and NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ (NSG lacking T, B, and 
NK cells) were purchased from Jackson Laboratory. Humanized-
BLT (hu-BLT; human bone marrow/liver/thymus) mice were 
prepared on NSG background as described previously (37, 38). 
To establish orthotopic tumors, mice were first anesthetized 
with isoflurane in combination with oxygen, and tumor cells 
were directly injected in the floor of mouth in suspension with 
10 μl HC Matrigel (Corning, NY, USA) (1 × 106 cells). Four to 
five weeks after the tumor injections, mice were euthanized and 
bone marrow, spleen, and blood were harvested and single cell 
suspensions were prepared (39).
elisa and Multiplex cytokine array Kit
Single ELISAs and multiplex assays were performed as described 
previously (36).
cancer stem cell Differentiation with nK 
cell supernatants
Supernatants from NK  cells were prepared and used for dif-
ferentiation of OSCSCs as described previously (35). Day 
13 supernatants from OC-expanded NK  cells were used for 
differentiation.
surface staining and cell Death assays
Staining was performed by labeling the cells with antibodies or PI 
as described previously (36, 40, 41). Flow cytometry analysis was 
performed using Beckman Coulter Epics XL cytometer (Brea, 
CA, USA) and results were analyzed using FlowJo vX software 
(Ashland, OR, USA).
51cr release cytotoxicity assay
The 51Cr release assay was performed as described previously (42).
statistical analysis
An unpaired, two-tailed Student’s t-test or one way ANOVA were 
performed to compare different groups depending on the experi-
mental design. The p-values were expressed within the figures 
as follows: ***p-value <  0.001, **p-value: 0.001–0.01, *p-value: 
0.01–0.05.
resUlTs
Preferential expansion of nK or T cells by 
Ocs or Dcs, respectively
We compared the activating effect of OCs, monocytes, and DCs 
on NK cell expansion and function. NK cells were activated with 
IL-2 and anti-CD16 mAb 18–20  h before their coculture with 
OCs and/or sAJ2. The combination of OCs and sAJ2 preferen-
tially expanded NK cells while maintaining a low proportion of 
T cells (Figures S1A,B in Supplementary Material). The rate of 
expansion and the levels of contaminating T cells in NK cultures 
were then compared between the cocultures with OCs, DCs, 
and monocytes treated with sAJ2. NK cells cocultured with OCs 
preferentially expanded NK cells, and the rate of contaminating 
T cells remained very low throughout the first 1–2 months of the 
culture (Figures 1A–D and 2A–F). By contrast, DCs preferen-
tially expanded T cells and the proportion of NK cells remained 
low. Although monocytes were also able to expand T cells, T cell 
expansion remained lower than those of NK cells. There was an 
initial increase in the proportion of T cells in all three cultures; 
however, in subsequent cultures, the rate of T  cell expansion 
decreased in the cocultures with OCs, whereas T cells continued 
expanding and were substantially increased in cultures with DCs. 
A steady state of T cell expansion can also be seen in cocultures 
with monocytes (Figures 1A,D).
Natural killer cells cocultured with OCs were able to lyse 
OSCSCs significantly more than NK  cells cocultured with 
monocytes or DCs, and there was a significant increase from day 
9 to day 15, correlating with the higher numbers of NK cells in 
coculture with OCs on day 15 (Figures 1A,C and E). IL-2- and 
anti-CD16mAb-activated NK cells cultured with OCs secreted 
significantly higher amounts of interferon (IFN)-γ, compared 
to NK  cells cocultured with monocytes or DCs (Figure  1F 
and Figure S1C in supplementary material). Upon analysis of 
NK cell expansion rate and population doubling (defined by the 
log of the ratio of the final count to the baseline count divided 
by the log of 2) it was found that OCs expanded NK  cells 
21,000- to 132,000-fold at day 20 and 300,000- to 5,100,000-
fold on day 31, with 17–21 population doublings within 4 weeks 
(Figures 1G,H).
Freshly isolated monocytes were compared with mature DCs 
and OCs for expression of key surface receptors. CD54 was 
upregulated on DCs and OCs, whereas MHC-I was decreased 
on DCs and OCs, when compared to monocytes (Figure S1D in 
FigUre 1 | continued
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Supplementary Material). Killer cell immunoglobulin-like recep-
tors (KIRs), killer cell lectin-like receptor G1, and MICA/B were 
higher on OCs, intermediate on monocytes, and very low on DCs 
(Figure  1I and Figure S1D in supplementary material). ULBP 
1–6 were high on monocytes, intermediate on OCs, and low on 
DCs (Figure 1I). NK cell receptors including CD94 and NKG2D 
were higher on OC-expanded NK cells (Figure 1J, lower row) as 
compared to untreated primary NK cells (Figure 1J, upper row). 
FigUre 1 | continued 
expansion of natural killer (nK) cells by osteoclasts (Ocs) and T cells by dendritic cells (Dcs). Monocytes were purified from human PBMCs and were 
cultured with GM-CSF (150 ng/ml) and interleukin (IL)-4 (50 ng/ml) for 8 days to generate DCs. To generate OCs, monocytes were cultured in alpha-MEM media 
containing M-CSF (25 ng/ml) and RANKL (25 ng/ml) for 21 days. For expansion, purified NK cells (1 × 106 cells/ml) were treated with the combination of IL-2 
(1,000 U/ml) and anti-CD16mAb (3 μg/ml) for 18 h before they were cocultured with autologous monocytes, DCs, or OCs in the presence of sAJ2 at 1:2:4 ratios 
(monocytes, DCs, or OCs:NK:sAJ2). Surface expression of CD3, CD16, and CD56 was analyzed at days indicated in the figure using flow cytometry, and culture 
medium was refreshed and supplemented with rh-IL-2 (1,000 U/ml) (a). Cells were cocultured as described in panel (a) and the numbers of expanded lymphocytes 
were assessed using microscopic determination (B). The numbers of NK cells (c) and T/NKT (D) cells were determined using the percentages of NK and T/
NKT cells (a) within the total expanding cells in panel (B). Cells were cocultured as described in panel (a) and cytotoxicity was determined on the days shown in the 
figure using the standard 4-h 51Cr release assay against the oral squamous carcinoma stem-like cells (OSCSCs). The lytic units 30/106 cells were determined using 
the inverse number of lymphocytes required to lyse 30% of OSCSCs × 100 (e). Supernatants were harvested from the coculture of NK with OCs as described in 
panel (a) on days 6, 9, 12, and 15, and interferon-γ secretion was determined using single ELISA (F). NK cells were cocultured with autologous OCs and expanded 
from 10 healthy donors as described in panel (a). Cumulative fold expansion of NK cells was calculated for each donor for 31 days (g), and population doubling 
was calculated based on the log of the ratio of the final count to the baseline count divided by the log of 2 (h). DCs and OCs were generated as described in panel 
(a) and 1 × 104 cells were used to analyze ULBPs, KIR2, KIR3, killer cell lectin-like receptor G1 (KLRG1), and MICA/B surface expressions using PE-conjugated 
antibodies and flow cytometric analysis. IgG2 isotype control antibody was used as control (i). Freshly isolated NK cells (upper row) and NK cells cocultured with 
autologous OCs and expanded as described in panel (a) (lower row) were used to analyze CD16, Nkp30, Nkp44, Nkp46, KIR2, KIR3, CD94, and NKG2D surface 
expression using, PE-conjugated antibodies. IgG2 isotype control antibody was used as controls (J).
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Expression of CD16 receptor was decreased on expanded 
NK cells when compared to primary NK cells (Figure 1J).
residual Population of T cells Purified 
from Oc-expanded nK cells Did not 
contribute to lysis by the nK cells
The majority of T  cell contaminants from OC-expanded 
NK  cells were CD8+ T  cells (Figure S2A in Supplementary 
Material). To determine whether contaminating T cells contrib-
uted to NK  cell mediated killing of OSCSCs or K562s, T  cell 
contaminants from day 9 OC-expanded NK cells were sorted 
out positively to obtain purified T  cells. Purified NK  cells or 
T cells (Figure S2B in Supplementary Material) were then used 
in 51Cr release assay against OSCSCs and K562s. As expected 
CD3+ T  cells isolated from OC-expanded NK  cells did not 
contribute to lysis of OSCSCs (Figure S2C in Supplementary 
Material) or K562s (Figure S2D in Supplementary Material). 
In addition, supernatants from NK cells secreted significantly 
higher levels of IFN-γ compared to T  cells (Figure S2E in 
Supplementary Material).
expansion of nK cells with Ocs remained 
high in the First and second Month, and 
Decreased substantially in the Third Month
Natural killer cells cultured with OCs expanded for 31–36 days 
while the percentages of contaminating T cells remained low 
(Figure 2A). Day 36 expanded NK cells were re-cultured with 
OCs for a second round of expansion and the NK expansion 
was continued for 27 days (Figure 2B). Similarly, the percent-
ages of T  cell expansion remained very low in the second 
round of NK  cell expansion with OCs (Figure  2B). Day 67 
expanded NK  cells were re-cultured with OCs for the third 
round of expansion; however, NK cells were gradually lost due 
to T cell expansion (Figure 2C). When the total numbers of  NK 
and T cells were determined during expansion, the numbers 
of NK cells remained high in the first and second month of 
expansion (Figures 2D–2I) and substantially decreased in the 
third month (Figures 2J–2L). No or slight levels of cell death 
could be observed in the expanding NK  cells in the three 
rounds of expansion with OCs (Figure  2M). The ability of 
NK cells to lyse cancer stem cells and secrete IFN-γ was gradu-
ally decreased from the first to second round of expansion, and 
in the third round, during which greater percentages of T cells 
expanded, these functions became minimal (Figures  2N–S). 
Interestingly, even though large numbers of NK cells were still 
expanding during the second round of stimulation with OCs 
from days 40–63, the levels of NK cell cytotoxicity and secretion 
of IFN-γ were substantially lower than those obtained from 
expanded NK cells in the first round of stimulation on days 
0–34 (Figure 2).
Ocs, But not K562 or Oscscs, expand 
nK cells and increase nK cell Function
Activated NK  cells were cultured with OSCSCs, K562, OCs, 
irradiated K562, or irradiated OCs in the presence of sAJ2 and 
the levels of NK expansion and their function were determined 
(Figures S3A–H in Supplementary Material). NK cell expansion 
and function (cytotoxicity and IFN-γ secretion) induced by either 
non-irradiated, irradiated K562, or OSCSCs was significantly 
lower than those induced by non-irradiated or irradiated OCs 
(Figure S3 in Supplementary Material).
Decreased cytotoxicity and lower iFn-γ 
secretion by nK cells from Patients 
coincides with increased expansion of T 
cells
When cultured with OCs, purified NK cells from cancer patients 
in comparison to healthy controls were unable to maintain the 
expansion of NK cells and indeed, by day 12, greater than half of 
the expanding cells were T cells. Moreover, by day 31, only 10% 
of the remaining cells in the culture were NK cells (Figures 3A,B; 
Figures S4A,B in Supplementary Material). In addition, when total 
numbers of expanded NK and T cells were determined within 
31 days of expansion in cancer patients in comparison to healthy 
FigUre 2 | continued
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controls, there were less expanding cells from cancer patients 
when compared to healthy controls, even though no or a slight 
increase in cell death could be seen in expanding NK cultures 
in patient cells as compared to healthy controls (Figures 3C,D; 
Figures S4C–F in Supplementary Material), and the levels 
of expanding T  cells were significantly higher than NK  cells 
(Figures  3E,F; Figures S4D,E in Supplementary Material). By 
contrast, NK  cells isolated from healthy donors maintained 
the expansion of NK cells and the levels of NK expansion were 
significantly higher than T cells (Figures 3B,E,F; Figures S4B,D,E 
in Supplementary Material). No or much lower proliferation of 
NK cells were observed with patient NK cells when compared to 
healthy NK cells at different days of culture (Figure 3E; Figure 
S4D in Supplementary Material).
FigUre 2 | continued
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FigUre 2 | reduced proportions of natural killer (nK) cells, nK cell-mediated cytotoxicity, and interferon (iFn)-γ secretion with each successive 
monthly re-stimulation of nK cell cultures with osteoclasts (Ocs) and saJ2 bacteria. Freshly purified NK cells were treated and cocultured with monocyte-
derived autologous OCs as described in Figure 1a. Surface expression of CD3, CD16 and CD56 was analyzed in 1 × 104 lymphocyte from cocultures at days 
indicated in the figure using flow cytometric analysis (a). After 36 days, when NK cells ceased to expand, they were re-cultured with fresh autologous OCs as 
described in Figure 1a. Surface expression of CD3, CD16, and CD56 was analyzed on the days indicated in the figure using antibody staining and flow cytometric 
analysis (B). On day 63, when cells ceased to expand, they were re-cultured with OCs as described and surface expression of CD3, CD16, and CD56 was analyzed 
on days shown in the panel (c). The numbers of expanded lymphocytes were assessed using microscopic determination (D,g,J) and the numbers of NK cells 
(F,i,l) and T/NKT (e,h,K) cells were determined using the percentages of NK and T/NKT cells within the total expanding cells (D,g,J). Cell death was determined in 
lymphocytes at days 36, 59, and 83 using propodium iodide staining and flow cytometric analysis (M). Freshly purified NK cells were treated and cocultured with 
autologous OCs as described in Figure 1a. Lymphocytes were then tested for cytotoxicity using the standard 4-h 51Cr release assay against the oral squamous 
carcinoma stem-like cells after 6, 13, 17, and 34 days of the coculture (n), 40 and 63 days of the coculture (O), or 76 and 92 days of the coculture (P). The lytic 
units 30/106 cells were determined using the method described in Figure 1e. The supernatants were harvested and IFN-γ secretion was determined using single 
ELISA using supernatants from days 6, 9, 12, 15, 18, and 21, (Q); days 40, 46, 51, 55, and 59 (r), and days 76, 83, 87, 92, and 97 (s).
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Patients’ NK  cells cultured with OCs lysed OSCSCs signifi-
cantly less when compared with the healthy NK  cells cultured 
with OCs (Figure 3G; Figure S4G in Supplementary Material). 
When normalized based on the number of NK cells, cytotoxic-
ity induced per NK  cell by patients was less when compared 
to NK  cells from healthy controls (Figure  3H; Figure S4H 
in Supplementary Material). OC-expanded patient NK  cells 
secreted significantly less IFN-γ when compared to healthy 
OC-expanded NK cells (Figure 3I; Figure S4I in Supplementary 
Material). OC-expanded oral cancer patients’ NK cells secreted 
significantly less IL-10 when compared to healthy NK  cells 
(Figure  3J), whereas those from pancreatic cancer patients 
secreted higher IL-10 when compared to healthy NK cells (Figure 
S4J in Supplementary Material). No significant differences could 
be observed for the levels of IL-6 secretion by healthy or cancer 
patients NK  cells (Figure  3K; Figure S4K in Supplementary 
Material). Thus, although cultures of NK cells from patients 
with different tumor types exhibited differences in individual 
cytokines such as IL-10, they all exhibited lower cytotoxicity and 
less IFN-γ secretion (Figures 3G–K; Figures S4G–K in supple-
mentary material). The levels of NKG2D surface expression were 
similar on healthy as compared to patient NK  cells expanded 
by the OCs (Figure  3L). The intensity of CD94 expression 
is higher on the surface of patient NK  cells as compared to 
healthy control (Figure 3L). KIR2, NKp30, NKp44, and NKp46 
expressions were lower on the surface of OC-expanded patient 
NK  cells when compared to healthy NK  cells (Figure  3L), 
whereas KIR3 expression was either the same or lower on the 
surface of OC-expanded patient NK  cells when compared to 
healthy NK  cells (Figure  3L).
supernatants from Patient expanded 
nK cells are less able to Differentiate 
Oscscs
Oral squamous carcinoma stem-like cells were treated with 
equal volumes of day 13 supernatants from patient and healthy 
donors for 18–20  h before the levels of CD44, B7H1, CD54, 
and MHC-I expressions were analyzed (Figure  3M). There 
was a 7.1-fold increase in MHC-I expression by healthy NK 
supernatants but only 2.56-fold increase was induced by patient 
NK supernatants (Figure 3M). For CD54 expression, a 13-fold 
increase was observed by healthy NK supernatants compared 
with a 2.1-fold increase with patient NK supernatants. As 
for B7H1, a 3.75-fold increase was observed by healthy NK 
supernatants compared with a 1.5-fold increase with patient NK 
supernatants. CD44 was decreased by healthy NK supernatants, 
whereas no decrease was observed by patient NK supernatants 
FigUre 3 | continued
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FigUre 3 | Purified natural killer (nK) cells cultured with osteoclasts (Ocs) from cancer patients expand more T cells than nK cells, mediate much 
lower cytotoxicity, and cytokine secretion compared to those expanded from healthy donors. Freshly purified NK cells from healthy donor and cancer 
patient were treated and cocultured with monocyte-derived OCs as described in Figure 1a. Surface expression of CD3, CD16, and CD56 was analyzed on 
expanding cells at days 0, 6, 9, 12, 15, 18, 21, 24, 27, and 31 of cancer patient (a) and healthy donor (B) using antibody staining followed by flow cytometric 
analysis. Cell death was determined on expanding NK cells from cancer patients and healthy donors at day 19 using propidium iodide (PI) staining and flow 
cytometric analysis (c). After 6, 9, 12, 15, 18, 21, 24, 27, and 31 days of coculture, expanded lymphocytes were assessed using microscopic determination (D). 
The numbers of NK cells (e) and T/NKT (F) cells were determined using the percentages of NK and T/NKT cells within the total expanding cells in panels (a,B). 
Cytotoxicity of lymphocytes was determined following overnight, 12, and 15 days of coculture using standard 4-h 51Cr release assay against oral squamous 
carcinoma stem-like cells (OSCSCs). The lytic units 30/106 cells were determined using the method described in Figures 1e,g. Lytic units from panel (g) were 
normalized based on per NK cells (h). The supernatants were harvested from the overnight, days 6, 9, 12, 15, 18, 21, 24, and 27 cocultures and IFN-γ (i), 
interleukin (IL)-10 (J), and IL-6 (K) secretion was determined using single ELISAs. Freshly purified NK cells from healthy donors, cancer patient with tonsillar 
carcinoma (patient.1), and pancreatic cancer (patient.2) were treated and cocultured with OCs as described in Figure 1a. Surface expressions of CD3, CD16, and 
CD56 were analyzed on lymphocytes from cocultures of day 21 for healthy donor and patient NKs, and day 87 (third stimulation) of healthy donors [(l) upper panel], 
and surface expression of Nkp30, Nkp44, Nkp46, KIR2, KIR3, CD94, and NKG2D was analyzed within CD16 positive cells [(l) lower panels]. IgG2 isotype control 
antibodies were used as controls (l). The supernatants were harvested from the cocultures on day 13, and the equal volumes of supernatants (200 μl) from each 
donor were used to differentiate OSCSCs for overnight, before the levels of MHC-I, CD54, CD44, and B7H1 surface expressions were determined on OSCSCs. 
IgG2 isotype control antibodies were used as controls (M). Cell death was determined in untreated and NK cell supernatant-differentiated OSCSCs using 
propodium iodide staining and flow cytometric analysis (n). Highly purified NK cells were treated with IL-2 (1,000 U/ml) and used to determine cytotoxicity against 
untreated and NK supernatant-differentiated OSCSCs in 4-h 51Cr release assay. The lytic units 30/106 cells were determined using the method described in 
Figure 1e (O).
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(Figure 3M). No significant cell death could be observed after 
treating OSCSCs with NK supernatants (Figure 3N). As shown 
in Figure  3O, 74% decrease in NK  cell-mediated cytotoxicity 
was observed when OSCSCs were treated with healthy NK 
supernatants, whereas only 33% decrease could be observed 
with patient NK supernatants (Figure 3O).
FigUre 4 | continued
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Oral Tumors in humanized Mice 
Preferentially expand T cells resulting in 
the loss of nK cytotoxicity While 
retaining iFn-γ secretion
Humanized-BLT mice were implanted with oral tumors and mice 
were sacrificed 4  weeks after tumor implantation. The spleens 
from hu-BLT mice were harvested, and T cells were sorted out. 
The flow-through cells containing NK and B cells (Figure S6 in 
Supplementary Material) were then treated with IL-2 and anti-
CD16mAb for 18–20 h before they were cultured with BLT-OCs. 
Even though tumor-bearing hu-BLT mice contained larger 
percentages of NK cells (Figure 4A), the expansion resulted in 
gradual and significant T cell expansion which started on day 6 
and continued to day 22, at which point 97% of the cells were 
T cells and only 1.1% were NK cells. By contrast, flow-through 
cells from hu-BLT mice with no tumor which contained less 
NK  cells initially, expanded NK  cells, and the levels rose from 
69.7% NK cells at day 6 to 97% NK cells at day 22 (Figure 4B). 
The levels of NK  cells when cultured with autologous OCs 
were increased in both animals from the initial day of culture, 
although mice with no tumor had a 27.66-fold increase from day 
0 to day 6, whereas tumor-bearing mice had a 7.5-fold increase 
(Figure 4B). The total numbers of expanded lymphocytes were 
slightly higher in tumor-bearing mice as compared to those 
without tumors (Figure 4C), with the majority of being T cells 
and not NK cells (Figures 4D,E).
OC-expanded NK cells from tumor-bearing mice were able 
to lyse OSCSCs significantly less than those of control mice 
without tumor (Figure  4F). In addition, when cytotoxicity 
FigUre 4 | spleen natural killer (nK) cells depleted of T cells from tumor-bearing humanized-BlT mice cultured with osteoclasts (Ocs) expand small 
fraction of contaminating T cells faster than nK cells obtained from healthy hu-BlT mice cultured with Ocs. Reconstituted BLT mice were orthotopically 
injected with 1 × 106 of human oral squamous carcinoma stem-like cells (OSCSCs) into the floor of the mouth. Disease progression and weight loss were monitored 
for another 4–5 weeks. Mice were sacrificed, spleens were harvested, and single cell suspensions were obtained as described in Section “Materials and Methods.” 
CD3+ T cells were sorted out using positive selection kit and the flow-through cells were analyzed for surface expression of human CD3/CD16/CD56 after staining 
with the respective antibodies. Isotype control antibodies were used as controls (a). CD3-negative cells (1 × 106 cells/ml) from hu-BLT mice were treated with the 
combination of interleukin (IL)-2 (1,000 U/ml) and anti-CD16mAb (3 μg/ml) for 18 h before they were cultured with OCs in the presence of sAJ2 at 1:2:4 ratios 
(OC:NK:sAJ2). Surface expression of CD3, CD16, and CD56 was analyzed on days 6, 10, 14, 18, and 22 using flow cytometric analysis (B). After 6, 10, 14, 18, and 
22 days of coculture, expanded lymphocytes were assessed via microscopic determination (c). The numbers of NK cells (D) and T/NKT (e) cells were determined 
using the percentages of NK and T/NKT cells within the total expanding cells. Cytotoxicity of NK cells cocultured for 10 and 18 days was determined using standard 
4-h 51Cr release assay against OSCSCs and the lytic units 30/106 cells were determined using inverse number of NK cells required to lyse 30% of OSCSCs × 100 
(F). Lytic units was normalized and adjusted per NK cell lysis against OSCSCs (g). The supernatants were harvested from the coculture on days 6, 10, and 13, and 
interferon (IFN)-γ (h), IL-10 (i), and IL-6 (J) secretion was determined using single ELISAs. Peripheral blood was collected post-mortem by cardiac puncture from 
hu-BLT mice and serum samples were harvested and analyzed for IFN-γ, IL-10, and IL-6 secretion using multiplex arrays (K).
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was assessed per NK  cell basis, less cytotoxicity was seen with 
NK  cells from tumor-bearing mice as compared to NK  cells 
from control mice without tumor (Figure  4G). OC-expanded 
NK cells from tumor-bearing mice secreted significantly higher 
IFN-γ (Figure 4H), lower IL-10 (Figure 4I), and slightly lower 
IL-6 (Figure  4J) when compared to the control mice without 
tumor. Sera from peripheral blood of tumor-bearing hu-BLT 
mice exhibited increased secretion of IFN-γ, IL-10, and IL-6 
as compared to the control mice with no tumor (Figure 4K).
il-15, in Part, Mediates expansion of  
nK cells by Ocs, Whereas il-12 is 
responsible for increased iFn-γ  
secretion by nK cells
We determined the levels of cytokines, chemokines, growth 
factors, and ligands secreted by primary NK  cells and day 6 
OC-expanded NK cells (Figure S7 in Supplementary Material). 
The majority of secreted cytokines, chemokines, growth factors, 
FigUre 5 | continued
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FigUre 5 | continued 
Blocking interleukin (il)-12, il-15, or a combination of both resulted in reduced natural killer (nK) cell expansion, nK cell-mediated cytotoxicity, and 
cytokine secretion. Freshly purified NK cells from a healthy donor were treated and cocultured with autologous osteoclasts as described in Figure 1a in the 
presence and absence of anti-IL-12, -IL-15, or a combination of anti-IL-12 and -IL-15 mAbs at 100 ng/ml and 1 μg/ml, respectively. Cocultures were replenished 
with IL-2 (1,000 U/ml) every 2 days. NK cells were counted using microscopy on days 6, 8, 12, 14, and 20 (a). On day 9 and day 15, 1 × 105 NK cells from each 
expanded samples were used in standard 4-h 51Cr release against oral squamous carcinoma stem-like cells (OSCSCs). The lytic units 30/106 cells were determined 
using inverse number of NK cells required to lyse 30% of OSCSCs × 100 (B). The supernatants were harvested from the cocultures on days 8, 12, 15 and 20, and 
IFN-γ secretion was determined using single ELISA (c).
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and ligands were higher by OC-expanded NK cells when compared 
to those secreted by the primary NK cells activated with IL-2 and 
anti-CD16mAb (Figure S7 in Supplementary Material). A 50–60 
fold higher induction of IL-12 and 20- to 26-fold higher IL-15 
secretion were seen by OC-expanded NK  cells as compared 
to primary NK  cells (Figure S7 in Supplementary Material). 
Addition of anti-IL-12 and/or anti-IL-15 mAbs significantly 
reduced cell expansion, with 1 μg/ml of anti-IL-15 having the 
largest effect (Figure 5A). The treatment with anti-IL-12 and/or 
anti-IL-15 did not affect the cytotoxic function of NK cells at day 
9 (Figure 5B), but cytotoxicity was inhibited significantly at day 
15 (Figure 5B). The levels of IFN-γ secretion by OC-expanded 
NK  cells were reduced more by anti-IL-12 when compared to 
anti-IL-15 treatment (Figure 5C).
addition of anti-cD3 antibody controls  
T cell expansion and increases  
Oc-expanded nK cells
Lymphocytes were treated with anti-CD3, and NK and T  cell 
expansions were assessed on different days (Figures 6A,B). Loss 
of forward and side scatter (Figures 6C,D), and elevation in DNA 
fragmentation as evidenced by an increase in sub G0/G1 peak in 
cell cycle analysis was obtained in anti-CD3 treated cells indicat-
ing loss of T cells (Figure 6E). Accordingly, the levels of NK cells 
increased in both patient and healthy donors (Figures  6A,B). 
The population which lost forward and side scatter was CD3+ 
T cells as determined by CD3 and CD16mAb staining (data not 
shown). In the absence of NK cells, anti-CD3mAb-treated T cells 
did not lose forward and side scatter (Figure S8 in Supplementary 
Material) nor exhibited cell death (data not shown). When cyto-
toxicity of NK cells was assessed before and after the addition of 
anti-CD3 mAb, NK cells from both healthy and patient donors 
had significantly lower cytotoxicity after the addition of anti-
CD3mAb, although the cytotoxic function of NK cells were still 
higher by healthy NK cells when compared to patient NK cells 
after the addition of anti-CD3mAb (Figure 6F). In contrast, the 
levels of IFN-γ secretion rose significantly in both healthy and 
patient NK cells after the addition of anti-CD3mAb indicating 
the induction of split anergy in NK cells by anti-CD3mAb bound 
T cells (Figure 6G).
DiscUssiOn
We have recently shown in in vivo and in vitro studies that OCs 
are major activators of NK cells (43). More importantly, single 
monthly stimulation with OCs was able to maintain expansion 
of super-charged NK  cells for over 2  months from healthy 
donors. In addition, the cytotoxic function of NK cells remained 
significantly higher during the first month and declined in the 
second month of expansion. At the present time, it is unclear why 
NK cell function continues to decline during the second month 
of stimulation even though large numbers of NK cells continue to 
expand. It is possible that additional signals are required for the 
maintenance of NK cell cytotoxicity at the second month and/or 
more frequent supplementation with OCs is required.
To our knowledge, using OCs as feeder cells is the best 
strategy for expanding large numbers of NK cells compared to 
those previously described (Table S1 in Supplementary Material). 
First, we obtained 21,000- to 132,000-fold expansion on day 20, 
and 0.3–5.1 million on day 31, with 17–21 population doublings 
within 4 weeks of expansion, which is a much higher rate than 
any previously reported method (Table S1 in Supplementary 
Material). Although cytotoxic function of expanded NK  cells 
across studies is difficult to compare due to different types of 
targets used, our strategy provides large numbers of NK  cells 
with significant capabilities to target and lyse cancer stem 
cells/ undifferentiated tumors and secrete IFN-γ (Table S1 and 
Figures S1 and S7 in Supplementary Material, Figure 3, Ref. S13). 
Moreover, we expand primary NK  cells with no or very little 
chance of transformation, which is known to influence NK cell 
function since most NK lines (such as YT, NK92, or NK-L) (44) 
or transfected NK cells tend to either lose all or most or some 
of their cytotoxic and IFN-γ secretion capabilities, respectively 
(45, 46). In addition, although anti-CD3 antibody treatment to 
maintain NK  cell expansion would be a good strategy to limit 
T cell expansion, the cytotoxic activity of such NK cells is lower 
due to significant split anergy induced in NK cells. This strategy 
could be great for inducing differentiation of cancer stem cells/
undifferentiated tumors due to a larger increase in IFN-γ secre-
tion; however, it may not be sufficient to lyse these tumors. This 
could be one reason why the use of NK cells in immunotherapy of 
solid tumors did not result in regression of the tumors in a small 
numbers of patients tested (46–48).
In contrast to OCs, DCs stimulated preferential expansion 
of small numbers of contaminating T cells in purified NK cells 
in healthy donors and the levels of T cells continued to rise for 
a month thereby decreasing the NK expansion. Accordingly, 
cytotoxicity was lost against OSCSCs. Interestingly, when the 
cytotoxicity of NK  cells was assessed at an earlier time point, 
in which similar proportion of NK cells was observed with OC 
and DC cultures, a rise in NK cytotoxicity could be observed 
by the NK cells cultured with OCs (data not shown). Similarly, 
there was an increase in IFN-γ secretion by NK  cells cultured 
FigUre 6 | addition of anti-cD3 antibody inhibits T cell expansion and increases osteoclast (Oc)-expanded natural killer (nK) cells. Freshly purified 
NK cells from healthy donors and cancer patients were expanded with OCs for 27 days, the cultures where then treated with 1000 U/mL rh-IL-2 and anti-CD3 
(1 μg/ml), before the numbers of NK cells (a) and T cells (B) were determined by microscopic evaluation on days 27, 29, 31, and 35. Loss of forward and side 
scatter was determined in healthy donors’ cells (c) and patients’ cells (D) treated as described in panels (a,B). Healthy donors’ and patients’ cells were stained with 
propidium iodide (PI) and analyzed for DNA fragmentation (e). Lymphocytes from day 31 culture were used in standard 4-hr 51Cr release against oral squamous 
carcinoma stem-like cells (OSCSCs). The lytic units 30/106 cells were determined using inverse number of NK cells required to lyse 30% of OSCSCs × 100 (F). The 
supernatants were harvested from the coculture on day 35 and IFN-γ secretion was determined using single ELISA (g).
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with OCs when compared to those cultured with DCs indicating 
that on a per cell basis, NK  cells secreted higher IFN-γ when 
cultured with OCs as compared to those cultured with DCs 
(Figure S1C in Supplementary Material). T cells sorted out from 
OC-expanded NK cells did not contribute to NK cell-mediated 
cytotoxicity of the NK targets, and the minimal cytotoxicity seen 
by the T cells was likely due to contaminating NK cells (Figures 
S2B–D in Supplementary Material). On the other hand, T cells 
sorted out from OC-expanded NK cells released IFN-γ, but the 
levels were lower than those released by NK cells (Figure S2E in 
Supplementary Material). When subsets of T  cells: CD8, CD4, 
and gdT  cells were sorted out from PBMCs and used in cyto-
toxicity assay, only NK cells were able to lyse OSCSCs and the 
residual cytotoxicity seen by the T cell subsets was due to small 
numbers of contaminating NK cells (data not shown and Figure 
S2F in Supplementary Material). OCs in comparison to DCs 
displayed higher expression of activating NK ligands, whereas 
they both demonstrated similar levels of differentiation antigen 
CD54. Interestingly, they both demonstrated lower levels of MHC 
class I expression when compared to monocytes (Figure S1D in 
Supplementary Material). In addition, IL-15 secretion appeared to 
be important for the proliferation of NK cells (Figure 5A) whereas 
IL-12 was important for the secretion of IFN-γ (Figure 5C). Both 
cytokines played a key role in cytotoxic function of NK cells when 
assessed at the later days as compared to earlier time points in 
expansion (Figure 5B).
In contrast to OCs, all the tumor cell lines tested regardless 
of whether they were non-irradiated or irradiated did not sup-
port the expansion of NK  cells long term, and in short term 
even though secretion of IFN-γ could be observed in cultures 
with K562 and OSCSCs, this effect was short lived (Figure S3 
in Supplementary Material). In agreement, K562 tumors were 
previously shown to be significantly less effective than EBV 
lymphoblastoid cell line (R69-LCL) in activating NK cells even 
in the presence of NK-activating cytokines (49, 50). In addi-
tion, OC-induced expansion was also compared to irradiated 
PBMCs, and it was found to be significantly inferior to that of 
OCs (data not shown). NK cells expanded by OCs demonstrated 
much higher levels of activating receptor expression including 
NKG2D, NKp46, NKp44, NKp30, CD94, and increased inhibi-
tory receptors KIR2 and KIR3 with much lower expression of 
CD16 receptor when compared to primary NK cells (Figure 1J, 
lower row). When comparing OC-expanded NK  cells from 
healthy donors, cancer patients had in general much lower 
receptor expression, and the levels were even less than those 
seen during third round of stimulated healthy NK cells which 
had lost significant cytotoxic and cytokine secretion capabili-
ties, and allowed for the expansion of T cells. Patients’ NK cells, 
similar to NK cells expanded by K562 and OSCSCs were short 
lived and had much lower cytotoxic and cytokine secretion 
capabilities. K562 or OSCSCs, unlike OCs, expressed lower 
levels of NK-activating ligands (Figure S1D in Supplementary 
Material), and lacked secretion of key cytokines responsible for 
the expansion of NK cells, since increase in these signals by OCs 
was able to elevate expansion and function of NK cells (Figure 
S7A in Supplementary Material). It remains to be determined if 
such signals by engineered K562s (Table S1 in Supplementary 
Material) are inferior to those delivered by the OCs since the 
rate of expansion of NK cells by engineered K562 cells is lower 
by a magnitude of 100-fold from OC-expanded NK cells (Table 
S1 and Figures S3A,B in Supplementary Material). In addition, 
continuous stimulation by the engineered K562s is required to 
maintain NK expansion whereas only one stimulation with OCs 
is sufficient to expand super-charged NK cells for over a month 
(51). Moreover, OC-expanded NK cells, unlike primary NK cells, 
withstand freezing temperatures quite well and retain their 
super-charged characteristics and expansion rates with no loss 
of viability or function (Figure S5 in Supplementary Material).
When OC were used to expand NK cells from cancer patients 
a very distinct profile was observed. OCs also expanded T cells 
from purified cancer patients’ NK cells early in the culture with 
decline in expansion of NK cells at different days. When assessing 
the function of patients’ NK cells after OC cultures a significant 
loss of NK cell cytotoxicity, and a decrease in IFN-γ secretion 
could be observed per NK cells (Figures 3G,I; Figures S4G–I in 
Supplementary Material). This observation is important since it 
indicates that faster expansion of contaminating small fraction 
of T cells in purified NK cultures in cancer patients correlates 
with loss of cytotoxic function of NK cells. Whether loss of NK 
cytotoxicity in cancer patients allows for the expansion of T cells, 
and/or expanding T cells have inhibitory effect on the expan-
sion of patient NK cells requires further investigation. It is also 
possible that T cells have in general greater survival advantage 
in comparison to NK cells and are able to proliferate faster than 
NK cells. These possibilities are presently under investigation in 
our laboratory. However, it is likely that the loss of NK cells may 
also provide the fertile ground for the continued growth and 
eventual metastasis of cancer stem cells.
To test whether OCs obtained from humanized mice 
implanted with tumors, similar to cancer patients’ OCs expand 
contaminating small fraction of T  cells within purified NK 
cultures, we implanted OSCSCs in the floor of the mouth. After 
5 weeks, mice were euthanized and splenic T cells were depleted 
before the remaining cells were cultured with autologous and 
allogeneic OCs and the rate of NK cell expansion were deter-
mined. Similar to healthy donors’ NK cells, NK cells from hu-
BLT mice without tumor expanded NK cells for a longer period 
of time, whereas those from tumor-bearing mice expanded the 
small fraction of contaminating T cells within the NK cultures 
faster favoring the expansion of T  cells. Interestingly, similar 
to the loss of NK cell cytotoxicity observed in cancer patients 
we also observed significant loss of NK  cell cytotoxicity in 
hu-BLT mice implanted with tumors which as indicated above 
may be the underlying mechanism for the expansion of T cells. 
However, OC-expanded NK + T cells from the tumor-bearing 
mice secreted higher levels of IFN-γ when compared to those 
from mice with no tumor, suggesting the potential induction of 
split anergy in NK cells to drive differentiation of cancer stem 
cells. This was found to be the case since tumor cells isolated 
from tumor bearing hu-BLT mice demonstrated higher dif-
ferentiation antigens including MHC class I and were resistant 
to NK cell-mediated cytotoxicity (data not shown). Therefore, 
even though NK cytotoxicity was lost in tumor-bearing BLT 
mice, higher IFN-γ secretion could partly inhibit the growth 
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and expansion of cancer stem cells by promoting differentiation 
of these tumors as shown previously (2).
It is hypothesized that the microenvironment in humanized 
mice is not conducive for the expansion of NK cells due to the 
lack of cross reactivity between murine and human IL-15, since 
the addition of human IL-15 promotes an increase in NK  cell 
numbers and function (39). However, if human NK  cells are 
reactive to mouse tissues and, therefore, are rendered hypo-
responsive, this may explain why T cells and B cells are signifi-
cantly expanded in numbers in humanized mice based on our 
findings. Inactivation or loss of NK function may allow faster 
and greater expansion of T and B  cells at the loss of NK  cells 
as seen with cancer patients’ NK  cells. Humanized mice are 
therefore a good model to study human cancers since in both 
cases lower function of NK cells may potentially expand T cells 
at the loss of NK cells.
Rapid expansion of T  cells and decreased NK  cell numbers 
in peripheral blood/tissues of cancer patients and in humanized 
mice could be detrimental for targeting MHC class I low targets 
including cancer stem cells/undifferentiated tumors by NK cells 
in order to minimize the tumor load. In addition, NK cells also 
provide large amounts of IFN-γ to promote optimal differentia-
tion of the cancer stem cells to increase MHC class I expression, 
thereby paving the road for targeting of NK differentiated tumors 
by CD8+ T cells. Thus, decline in the numbers and function of 
NK cells in cancer patients may not only prevent control of cancer 
stem cell/undifferentiated tumors but it will also decrease expan-
sion of CD8+ T cells leading to an increase in tumor growth. Thus, 
restoration of NK cell numbers and function in cancer patients 
will be important to establish effective control of tumor growth.
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